trending Market Intelligence /marketintelligence/en/news-insights/trending/53LtkCcUowW0n59TNYf-Xg2 content esgSubNav
In This List

Mylan gets US FDA approval for 1st generic of Allergan's Estrace Cream

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Mylan gets US FDA approval for 1st generic of Allergan's Estrace Cream

Mylan NV launched its Estradiol vaginal cream 0.01% in the U.S. after final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for the product to treat vulvar and vaginal atrophy.

Estradiol vaginal cream 0.01% is the first generic version of Allergan plc's Estrace Cream.

Estradiol vaginal cream 0.01% had U.S. sales of about $449 million for the 12 months ending Oct. 31, according to IQVIA.